China, AstraZeneca

AstraZeneca falls as fraud investigation reportedly expands in China (update)
An insurance fraud investigation linked to AstraZeneca (AZN) expands in China involving dozens of senior executives. Read more here.
AstraZeneca shares fall on report of potential China probe fallout
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fraud case in the country's pharma sector in years.
AstraZeneca stock tanks over fears of expanding China fraud probe
AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially escalating insurance fraud investigation in China. | AstraZeneca’s stock price dropped by 8.
AstraZeneca Falls Most Since 2020 as China Probe Fears Mount
AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns over a Chinese probe into the UK drugmaker.
AstraZeneca Stock Falls on China Probe Fears
AstraZeneca shares fell 8% in London Tuesday, the biggest drop in four years following a fresh report that a Chinese investigation of the company has widened. AstraZeneca said last week that its China chief,
Report finds China targeted AstraZeneca in fraud probe over cancer treatment
The pharmaceutical giant, whose China chief is now under investigation, was previously at the centre of insurance scam cases, report says.
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
Key Takeaways AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated ...
AstraZeneca’s China business under spotlight amid fraud case
AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...
AstraZeneca share move on China concerns ‘overdone,’ says BofA
BofA notes that AstraZeneca (AZN) shares are down greater than 10% in the last few days on the back of China concerns around the ongoing ...
Why Is AstraZeneca Stock Sinking On Tuesday?
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
STAT1d
Probe of AstraZeneca executive in China raises questions about company’s tactics
China's investigation of AstraZeneca's top executive in the country is raising questions about the company's tactics there.
AstraZeneca’s Stock Drop Overreaction: Buy Rating Amid China Investigation Concerns
Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.